This is a preview of subscription content, access via your institution.



References
- 1.
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol 2019;26:2065-123. https://doi.org/10.1007/s12350-019-01760-6.
- 2.
Longhi S, Quarta CC, Milandri A, Lorenzini M, Gagliardi C, Manuzzi L et al. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid 2015;22:147-55. https://doi.org/10.3109/13506129.2015.1028616.
Funding
This work was supported by the Lawson Research Institute, London, Ontario, Canada.
Author information
Affiliations
Corresponding author
Ethics declarations
Disclosures
Dr. Cigdem Akincioglu is a consultant for Pfizer. Drs. Rami M. Abazid, Jonathan G. Romsa, James C. Warrington, Robert Z. Stodilka, Ryan A. Davey, Sabe De, David L. Laidley, William C. Vezina, and William C. Vezina have nothing to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Abazid, R.M., Romsa, J.G., Warrington, J.C. et al. Tc-99m pyrophosphate left atrial uptake in patients with atrial fibrillation and cardiac amyloidosis. J. Nucl. Cardiol. (2021). https://doi.org/10.1007/s12350-020-02508-3
Received:
Accepted:
Published: